A Multicenter, Phase III, Randomized Controlled Trial Comparing Camrelizumab Plus Apatinib and Eribulin Versus Physician's Choice Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Camrelizumab (Primary) ; Eribulin (Primary) ; Rivoceranib (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- 26 Mar 2025 New trial record